Core Insights - NRx Pharmaceuticals and neurocare Group AG have formed a partnership to establish a nationwide network of clinics for integrated neuroplastic care targeting Depression, PTSD, and other serious mental health disorders [1][4] Group 1: Partnership and Objectives - The partnership aims to combine Transcranial Magnetic Stimulation (TMS) with ketamine and other neuroplastic drugs, alongside hyperbaric oxygen therapy and psychotherapy, to improve treatment outcomes for First Responders suffering from PTSD and Depression [1][2] - The goal is to provide innovative neuroplastic therapy accessible within driving distance for all Americans by the end of 2026, addressing the needs of over 50 million individuals in the US and 500 million globally affected by these conditions [4][5] Group 2: Clinical Efficacy and Research - Recent studies indicate that the integration of TMS with neuroplastic drugs has achieved an 87% response rate and a 72% remission rate in patients with treatment-resistant depression, although further research is needed [2][6] - Pilot programs have shown high success rates in combining TMS, neuroplastic drug treatment, hyperbaric oxygen, and psychotherapy for First Responders [6] Group 3: Existing Infrastructure and Future Plans - The partnership will utilize the existing network of 20 neurocare clinics and over 400 Apollo TMS devices across the US to facilitate the integrated treatment program [4][6] - The collaboration seeks to create a standardized approach to treatment protocols and clinical training, leveraging neurocare's expertise in neuromodulation technology and NRx's neuroplastic drug development [3][6] Group 4: Company Backgrounds - neurocare Group AG has developed a platform for neuroplastic therapy, including the Apollo TMS device, and operates over 40 clinics internationally, with annual sales exceeding €35 million in 2025 and projected to exceed €50 million in 2026 [8] - NRx Pharmaceuticals is focused on developing therapeutics for central nervous system disorders, with products like NRX-100 and NRX-101 targeting suicidal depression and bipolar depression, respectively [9][10]

Core Viewpoint - NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, is set to provide a corporate update on December 2, 2025, focusing on recent clinical, regulatory, and operational developments [1]. Company Overview - NRx Pharmaceuticals specializes in Neuroplastic Therapies aimed at treating central nervous system disorders, including suicidal depression, PTSD, anxiety, and Autism [3]. - The company is developing two key products: NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral D-cycloserine/lurasidone [3]. - NRX-100 has received Fast Track Designation for treating suicidal ideation in depression, while NRX-101 has been granted Breakthrough Therapy Designation for suicidal bipolar depression [3]. - An Abbreviated New Drug Application for NRX-100 has been filed, with a launch anticipated in July 2026 [3]. Subsidiary Information - HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is focused on creating a network of interventional psychiatry clinics that provide various therapies, including ketamine and transcranial magnetic stimulation [4]. - HOPE Therapeutics is the first network in Florida to offer the AMPA One Day (ONE-D) treatment, which combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine for treatment-resistant depression [4].

Core Insights - NRx Pharmaceuticals has made significant progress in advancing its corporate objectives and has entered revenue-generating activities for the first time in 2025 [2] - The company is focusing on two main products: NRX-100 for suicidal depression and NRX-101 for bipolar depression, with both products receiving regulatory designations to expedite their development [3][4] Financial Performance - For the quarter ended September 30, 2025, NRx Pharmaceuticals reported a loss from operations of $4.0 million, an increase from a loss of $3.0 million in the same quarter of 2024, primarily due to increased research and development expenses [14] - The company reported revenue of approximately $240,000 for the first time, driven by the acquisition of Dura Medical, which closed on September 8, 2025 [14] - As of September 30, 2025, the company had approximately $7.1 million in cash and cash equivalents, which would increase to $10.3 million after accounting for a subscription receivable [14][16] Product Development and Regulatory Updates - NRX-100 is being developed through both an NDA under FDA Fast Track designation and an ANDA for a preservative-free ketamine product, with the generic ketamine market estimated at approximately $750 million [3][6] - The NDA for NRX-100 is expected to be completed in Q4 2025, incorporating Real World Efficacy Data from over 60,000 patients [4] - NRX-101 has shown promising Real World Efficacy data, indicating that it can double the antidepressant and anti-suicidal effects of Transcranial Magnetic Stimulation (TMS) [10] Corporate Strategy and Expansion - HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is expanding its network of interventional psychiatry clinics, with three facilities currently operational in Florida and plans for more by year-end [6][12] - The company is actively pursuing additional acquisitions to enhance its clinic network, with potential revenue from these acquisitions estimated to exceed $20 million annually [15] - NRx Pharmaceuticals is also working on a nationwide expanded access program for NRX-101, allowing physicians to provide the medication at no charge to patients [10]

Core Insights - HOPE Therapeutics has initiated patient care for treatment-resistant depression using the Ampa One Day (ONE-D) protocol, marking a significant advancement in TMS therapy [1][2] - The Ampa device has shown promising results with an 87% response rate and a 72% remission rate in nonrandomized trials when combined with D-cycloserine and lisdexamfetamine [1][5] - The ONE-D protocol reduces the treatment duration from 90 days to a single day, offering a new paradigm for patients suffering from severe depression [2][3] Company Overview - HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is focused on building a network of interventional psychiatry clinics that provide various therapies, including TMS and neuroplastic medications [4] - The company is expanding its presence in Florida, with plans to operate six clinic locations by the end of 2025 [2][5] - Dr. Rebecca Cohen, the Medical Director of HOPE, is the first Ampa-certified psychiatrist in Florida, leading the deployment of the Ampa device [5] Treatment Protocol - The ONE-D protocol combines TMS with physician-prescribed D-cycloserine and lisdexamfetamine, aiming to achieve remission from treatment-resistant depression [4][5] - D-cycloserine has been shown to enhance the effectiveness of TMS significantly, with studies indicating a more than two-fold increase in treatment efficacy [1][3] Research and Development - NRx Pharmaceuticals is developing NRX-100 and NRX-101, targeting central nervous system disorders, including suicidal depression and PTSD [5][6] - NRX-101 has received Breakthrough Therapy designation for treating suicidal bipolar depression, highlighting the company's commitment to addressing critical mental health issues [6]

Core Insights - HOPE Therapeutics, Inc. has acquired a strategic interest in Cohen and Associates, LLC, integrating it into the HOPE Network, with Dr. Rebecca Cohen appointed as Medical Director overseeing care standards in Florida [1][9] Company Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focusing on building a network of interventional psychiatry clinics offering treatments such as ketamine and Transcranial Magnetic Stimulation (TMS) for patients with suicidal depression and related disorders [7] - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression and PTSD, with products like NRX-100 and NRX-101 [6] Leadership and Expertise - Dr. Rebecca Cohen is a recognized expert in TMS and has a strong academic background, having founded her practice in 2014 as one of the first dedicated interventional psychiatry practices in the U.S. [3][9] - The leadership team at HOPE, including Dr. Cohen and Stephen Durand, RN, aims to advance interventional psychiatry and expand treatment options for patients [4][5] Strategic Goals - The acquisition of Cohen, LLC is expected to enhance HOPE Therapeutics' revenue and EBITDA, with immediate expansion plans in Western Florida and Palm Beach [9]

Core Insights - NRx Pharmaceuticals and its subsidiary HOPE Therapeutics will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025 [1][2] - The presentation will include a corporate update and plans to launch a low-dose D-Cycloserine product, which has shown to more than double the effectiveness of Transcranial Magnetic Stimulation in treating depression [2] - NRx Pharmaceuticals is actively involved in treating veterans with suicidal depression and PTSD, collaborating with the US Department of Veterans Affairs [2] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD [4] - The company is developing NRX-100 (intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation and NRX-101 receiving Breakthrough Therapy Designation for treating suicidal bipolar depression [4] - NRx has recently re-filed an Abbreviated New Drug Application for NRX-100 and initiated a New Drug Application filing for the treatment of suicidal ideation in patients with depression [4] HOPE Therapeutics Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focused on building a network of interventional psychiatry clinics [5] - The clinics will offer treatments such as ketamine, Transcranial Magnetic Stimulation, and Hyperbaric Oxygen Therapy for patients with suicidal depression and related disorders [5] - HOPE Therapeutics aims to enhance the clinical benefits of NMDA-targeted drug therapy through a digital therapeutic-enabled platform [5]

Core Viewpoint - NRx Pharmaceuticals has re-filed its Abbreviated New Drug Application (ANDA) for KETAFREE™, a preservative-free IV ketamine formulation, following FDA approval of its Suitability Petition for the proposed strength of the drug [1][6]. Industry Overview - The current annual ketamine market is estimated at $750 million, with projections indicating growth to $3.35 billion globally by 2034 [2][6]. - An estimated 5.1 million Americans have received ketamine for medical uses, a number that continues to rise due to increased clinical focus [2]. Company Developments - NRx Pharmaceuticals aims to capture a significant share of the ketamine market and is seeking priority review from the FDA due to a severe drug shortage [2][4]. - The company has filed a citizen's petition to remove benzethonium chloride (BZT), a neurotoxic substance, from ketamine formulations intended for intravenous use [3][6]. - NRx's KETAFREE™ formulation is designed to eliminate toxic preservatives, aligning with current health priorities to remove harmful substances from drugs [6][7]. Manufacturing and Regulatory Context - The manufacturing of KETAFREE™ is in partnership with Nephron Pharmaceuticals, supporting the U.S. initiative to reshore critical drugs [4][6]. - The ANDA formulation is distinct from the New Drug Application (NDA) for NRX-100, which has received Fast Track Designation for treating suicidal ideation in depression [5][6]. Clinical Data and Future Prospects - NRx anticipates submitting clinical trial data from over 1,000 patients and real-world data from more than 180,000 patients, demonstrating the efficacy of ketamine compared to placebo and electroconvulsive therapy [5][6].

Core Insights - NRx Pharmaceuticals, Inc. is preparing to launch HOPE Therapeutics clinics in Fall 2025, focusing on treating suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction through a unique residential program that combines various therapies [1][6] - The company recently raised over $8.8 million from biotechnology investors to support its initiatives, with no variable rate features involved in the offering [3][6] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression and PTSD, utilizing its NMDA platform [5] - The company is advancing neuroplastic drug development, including NRX-100 (intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation and NRX-101 receiving Breakthrough Therapy Designation for specific depression treatments [5][7] HOPE Therapeutics Initiative - HOPE Therapeutics will be the first program in the nation to integrate neuroplastic drugs with established treatments like transcranial magnetic stimulation and hyperbaric oxygen therapy, aiming for a response rate exceeding 90% [3][6] - The program will also include nutritional therapy and outdoor activities, creating a comprehensive treatment environment [1][3] Advisory Board and Leadership - Matthew Rockefeller has joined the advisory board of HOPE Therapeutics, enhancing the initiative's leadership and strategic direction [1][6] - The initiative is supported by prominent figures from leading family offices, emphasizing collaboration and innovation in addressing mental health challenges [2]

Core Insights - NRx Pharmaceuticals is set to launch HOPE Therapeutics clinics in Fall 2025, focusing on treating suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction through a unique one-week residential program that combines various therapies [1][5] - The program will be the first of its kind in the nation, integrating neuroplastic drugs like ketamine, transcranial magnetic stimulation, and hyperbaric oxygen therapy, along with nutritional therapy and supportive therapy [1][6] - The company recently raised over $8.8 million from biotechnology investors to support its initiatives, with no warrants or variable rate features involved [3][5] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression and PTSD [4] - The company is advancing neuroplastic drug development, particularly NRX-100 (intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression [4] - HOPE Therapeutics, a subsidiary of NRx, aims to create a network of interventional psychiatry clinics offering innovative therapies for patients with suicidal depression and related disorders [6] Key Partnerships and Initiatives - Matthew Rockefeller has joined the advisory board of HOPE Therapeutics, enhancing the company's strategic direction [1][3] - The Global Passion Project, founded by Andrea Cartier Bartzen, emphasizes collaboration and innovation to address global challenges like suicidal depression and PTSD [2]

Core Insights - HOPE Therapeutics, Inc. has received final clearance from the Florida Agency for Health Care Administration to close the acquisition of Dura Medical LLC, which is a revenue-generating and EBITDA positive entity [1][8] - Dura Medical specializes in precision treatment for mental health and chronic pain, utilizing advanced interventional psychiatry procedures [2][8] - The acquisition is expected to enhance HOPE's revenue and EBITDA, contributing to its expansion in Florida and beyond [5][8] Company Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focusing on building a network of interventional psychiatry clinics that provide treatments such as ketamine therapy and Transcranial Magnetic Stimulation (TMS) [9] - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression and PTSD [6] Dura Medical's Mission and Services - Dura Medical aims to reduce suicide rates in the community, with a goal to treat over 10,000 individuals by 2026 [4] - The clinic offers a comprehensive range of services, including Ketamine Infusion Therapy, TMS, and Spravato®, targeting conditions like depression, PTSD, and anxiety [2][3] Regulatory and Strategic Developments - The acquisition of Dura Medical is part of a broader strategy that includes previous acquisitions aimed at expanding coverage along the West Coast of Florida [8] - The intended closing of the acquisition is subject to standard closing conditions, indicating a structured approach to regulatory compliance [5][8]